Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.
Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.
By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.
By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.
Lymphoma is the most common type of blood cancer, with over 400,000 people diagnosed around the world each year.
Chronic lymphocytic leukaemia (CLL) is a type of cancer in which the bone marrow too many lymphocytes (a type of white blood cell). Early on there is typically no symptoms. Later non-painful lymph node swelling, feeling tired, fever, night sweats, or weight loss for no clear reason may occur.
It begins in a certain type of cell of the immune system (lymphocytes, or white blood cells) and can be divided into two main categories – Hodgkin lymphoma, and Non-Hodgkin lymphoma (NHL).
NHL is the more common of the two and can be further categorised as indolent (slow growing) or aggressive (fast growing), depending on the speed with which the cancer grows. Follicular lymphoma is the most common indolent form of the disease and diffuse large B-cell lymphoma (DLBCL) is the most common aggressive form.
Leukaemia is the second most common form of blood cancer, with over 300,000 people diagnosed globally each year. The type of leukaemia that a person has is dependent on which type of blood cell – white or red – becomes cancerous.
The four main types of leukaemia include acute lymphocytic leukaemia (ALL), chronic lymphocytic leukaemia (CLL), acute myeloid leukaemia (AML), and chronic myeloid leukaemia (CML).
Learn more about the latest advances in Roche lymphoma and leukaemia research.
This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.